查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439672

泌尿系結石管理設備-全球市場回顧、競爭格局、市場預測（2030年）

Urolithiasis Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

2023年，全球泌尿系結石管理設備市場規模將達到15.3108億美元，到2030年將達到19.6312億美元，2024-2030年預測期間複合年增長率為4.27%，預計將增長。 由於尿路結石或腎結石盛行率的上升，市場呈現出正面的成長。 此外，肥胖等久坐的生活方式是腎結石形成的危險因素，產品設計的創新、終末期腎病的風險增加、老年人口的增加以及對治療方案的認識提高預計將在 2024 年至 2030 年間增加.在預測期內為市場成長做出貢獻。

泌尿道結石治療設備的市場動態

由於各種原因，泌尿結石管理設備市場的產品需求正在增加。 關鍵因素包括全世界尿路結石盛行率的增加。

根據歐洲泌尿外科協會（2019）的數據，尿路結石的盛行率從 1% 到 20% 不等，在加拿大、瑞典、美國等生活水準較高的國家，盛行率腎結石的發生率相當高（超過10%）。

根據英國泌尿科醫師協會（2022 年）的數據，腎結石很常見。 接受CT掃瞄的患者有8%的幾率患有腎結石，並且自20世紀初以來發病率一直在穩步上升。 此外，十分之一（9%）的人在一生中會患上結石。 男性比女性稍微更容易受到影響。 所有年齡層的患者都可能出現結石，但首次出現結石的高峰年齡是約 45 歲。

根據美國國家腎臟基金會 (2022) 的數據，每年有超過 50 萬人因腎結石問題前往急診室就診。

此外，久坐的生活方式增加，例如過量飲酒和減少液體攝取量，也可能導致腎結石的形成。 此外，由於不良飲食習慣和缺乏運動等久坐生活方式，肥胖是形成腎結石的高風險因素，其負擔的增加也可能促進泌尿結石管理設備市場的成長。是一種性別。

根據世界衛生組織（WHO）2022年數據，2016年全球肥胖人數約6.5億。 各種研究也表明，肥胖者會產生更多的尿酸和草酸鈣結石。

此外，老年人更容易形成腎結石，增加末期腎病的風險。 根據《2019年世界人口展望》，2019年全球65歲以上人口有7.03億人。 因此，隨著老年人口的增加，尿路結石盛行率增加，從而推高對尿路結石治療設備的需求，進而推動全球尿路結石治療設備市場的成長。

然而，輸尿管鏡設備的高成本以及內出血失血等術後併發症等某些因素可能會對泌尿系結石治療設備市場的成長產生一定的限制。

COVID-19 大流行的爆發導致急診就診人數大幅減少。 此外，門診預約被推遲，虛擬和電話諮詢的需求增加。 這些變化導致由於醫院床位、麻醉和治療能力以及醫務人員短缺而造成治療的嚴重延誤，對全球泌尿道結石管理設備市場產生了負面影響。

泌尿道結石治療設備市場區隔分析

在泌尿道結石治療設備市場的治療領域，體外震波碎石機 (ESWL) 預計在預測期內（2024-2030 年）將佔較高的市場佔有率。 這可能是由於與這些設備相關的某些功能所造成的。

該產品領域的高市佔率可歸因於越來越多的患者採用這些設備和快速治療。 ESWL 的主要優點是治療完全非侵入性，因為結石治療不涉及皮膚切口或使用侵入性手術器械。 相反，它使用衝擊波將結石破碎成小塊，並通過輸尿管將其從膀胱排出。

本報告研究和分析了全球泌尿結石管理設備市場，提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。

目錄

第1章泌尿道結石管理設備市場報告簡介

第 2 章泌尿結石管理設備市場執行摘要

  • 調查範圍
  • 市場概覽
  • 競爭評估

第3章監理與專利分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第4章泌尿道結石治療器材市場主要因素分析

  • 泌尿道結石管理設備市場驅動因素
    • 尿結石或腎結石的盛行率增加
    • 久坐的生活方式是形成腎結石的危險因子
    • 產品設計創新
    • 罹患末期腎病的風險增加
    • 老年人口增加
  • 泌尿道結石治療設備市場的限制與挑戰
    • 輸尿管鏡設備成本高
    • 術後併發症
  • 泌尿道結石管理設備的市場機會
    • 需要先進設備
    • 擴大拋棄式輸尿管鏡檢查的機會

第5章波特對泌尿結石管理設備市場的五力分析

第6章COVID-19對泌尿結石治療設備市場的影響分析

第7章泌尿道結石治療器械市場佈局

  • 依類型
    • 診斷
    • 治療
  • 按最終用戶
    • 醫院
    • 門診手術中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他領域

第 8 章泌尿系結石管理設備市場：全球公司佔有率分析 - 3 至 5 家主要公司

第9章泌尿結石治療設備市場的公司與產品概況

  • Boston Scientific Corporation
  • EMS Urology
  • Advin Health Care
  • Inceler Medikal Co. Ltd.
  • Walz Elektronik GmbH
  • DirexGroup
  • Medispec Ltd.
  • Richard Wolf GmbH
  • STORZ MEDICAL AG
  • Olympus
  • General Electric Company (GE Healthcare)
  • ESAOTE SPA
  • Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
  • BK Medical Holding Company, Inc.
  • Hitachi Medical Systems
  • Laborie
  • DRAMINSKI S. A.
  • ACE Medical Devices Pvt. Ltd.
  • Siemens Healthcare Private Limited
  • Vimex Sp. z o.o.

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

Product Code: DIMDCL0512

Urolithiasis Management Devices Market By Type (Diagnostics [X-Ray, Computed Tomography, Ultrasound, Others], Treatment [Shock Wave Lithotripters {Intracorporeal, Extracorporeal}, Ureteroscopes {Semi-Rigid, Flexible}, Stone Retrieval Devices, Others], By End-User (Hospitals, Ambulatory Surgical Centers, Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of urolithiasis and sedentary lifestyle

The global urolithiasis management devices market was valued at USD 1,531.08 million in 2023, growing at a CAGR of 4.27% during the forecast period from 2024 to 2030 to reach USD 1,963.12 million by 2030. The Urolithiasis Management Devices market is witnessing positive growth owing to the rising prevalence of urolithiasis or nephrolithiasis. In addition, sedentary lifestyle such as obesity which is a risk factor for the development of kidney stones, innovation in product design, increased risk of end-stage renal failure, growing geriatric population, and intensifying awareness for the procedure is thereby contributing to the growth of the Urolithiasis Management Devices market during the forecast period from 2024-2030.

Urolithiasis Management Devices Market Dynamics:

The Urolithiasis Management Devices market is witnessing a growth in product demand owing to various reasons. The key factor includes the rising prevalence of urolithiasis across the globe.

According to the European Association of Urology 2019, the prevalence rates for urinary stones vary from 1% to 20%, and in the countries with a high standard of life such as Canada, Sweden, or the US, renal stones prevalence is significantly high (>10%).

As per the British Association of Urological Surgeons 2022, Kidney stones are common. Patients undergoing a CT scan have an 8% chance of having kidney stones and its incidence has been steadily increasing since the early 20th century. Moreover, 1 in 11 people (9%) will get stone symptoms during their lifetime. Men are affected slightly more often than women. Patients of all ages suffer from stones, but the peak age for a first stone is around the age of 45.

According to the National Kidney Foundation 2022, over half a million people go to emergency rooms for kidney stone problems every year.

Moreover, a rise in sedentary lifestyle such as excessive consumption of alcohol, less consumption of water could also lead to the development of kidney stones. In addition, the growing burden of obesity among the population, a high-risk factor for the development of renal calculi, due to sedentary lifestyles such as poor dietary habits and lack of physical activities could also contribute to the Urolithiasis Management Devices market growth.

As per the World Health Organization (WHO) 2022 data, there was around 650 million obese population worldwide in the year 2016. Also, according to various studies, obese people develop more uric acid stones and calcium oxalate stones.

Also, the aging population is more prone to the formation of kidney stones and an increased risk of end-stage renal failure. As per the World Population Prospects, 2019, there were 703 million older persons aged 65 or over in 2019 globally. Therefore, as the aging population increases, there will be more prevalence of urolithiasis, which will eventually boost the demand for Urolithiasis Management Devices which will drive the growth of the Global Urolithiasis Management Devices market.

However, certain factors such as the high cost of ureteroscope devices and the postoperative complications like blood loss during internal bleeding may be certain limiting factors of the Urolithiasis Management Devices market growth.

The outbreak of the COVID-19 pandemic caused a significant decrease in emergency department visits. Moreover, there was a delay in outpatient clinic appointments which pushed the need towards virtual or telephone clinics. Due to a lack of in-hospital beds, anesthesia or procedural slots, and healthcare professionals, these changes created a significant backlog in the treatment, thereby creating a negative impact on the Global Urolithiasis Management Devices market.

Urolithiasis Management Devices Market Segment Analysis:

Urolithiasis Management Devices Market By Type (Diagnostics [X-Ray, Computed Tomography, Ultrasound, Others], Treatment [Shock Wave Lithotripters {Intracorporeal, Extracorporeal}, Ureteroscopes {Semi-Rigid, Flexible}, Stone Retrieval Devices, Others], By End-User (Hospitals, Ambulatory Surgical Centers, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Treatment segment of the Urolithiasis Management Devices market, the Extracorporeal Shock Wave Lithotripters (ESWL) is estimated to hold a higher share in the Urolithiasis Management Devices market during the forecast period (2024-2030). This can be attributed to the specific features associated with these devices.

The large market share of this product segment can be attributed to the growing patient adoption of these devices and quick treatment. The main benefit of ESWL is that the treatment is totally non-invasive, as it does not involve any skin incisions or the use of any invasive surgical instruments to treat the stone. Instead, shock waves are utilized to shatter the stone into tiny fragments that flow through the ureter and out of the bladder.

It also has other advantages such as reduced pain, quick recovery time, and shorter hospital stays. This treatment method is chosen by a majority of the patient and physician population.

ESWL is suited for small stones as well as certain stones present in the upper portion of the ureter. Moreover, multiple stones can also be treated with ESWL. Therefore, it is expected that with such advantages offered by the Extracorporeal Shock Wave Lithotripsy Devices this technology is expected to increase its penetration in coming years, thus this will drive the segment to grow during the forecast period, which will have a positive impact on the overall Global Urolithiasis Management Devices Market growth.

Furthermore, Extracorporeal Shock Wave Lithotripsy Devices are gaining commercial acceptability, which also improves market penetration. All these advantages of these devices make physicians more inclined to use Extracorporeal Shock Wave Lithotripsy Devices.

Hence, all the above-mentioned factors are expected to drive the segment growth of the Urolithiasis Management Devices market.

North America is expected to dominate the overall Urolithiasis Management Devices Market:

Among all the regions, North America is expected to account for the largest share in the Global Urolithiasis Management Devices market. Factors such as the growing prevalence of stone formations causing urolithiasis and increased risk of end-stage renal disease among the population, rising product approvals are expected to aid in the growth of the North America Urolithiasis Management Devices Market.

As per the Canadian Urological Association guidelines 2022, globally, the prevalence of urolithiasis is steadily increasing, and though some regional variability exists, contemporary estimates report up to 10-12% of men and 7-8% of women now suffer from nephrolithiasis.

Moreover, according to the US Department of Health and Human Services 2022, end-stage renal disease (ESRD) is a significant public health problem in the United States and a major source of suffering and poor quality of life for those afflicted.

Another factor responsible for the growth of the Urolithiasis Management Devices market is the launch of new products in the region. For instance, in 2019, Dornier Medtech launched and announced the immediate availability of its new AXIS single-use digital flexible ureteroscope in the US.

In 2019, Shockwave Medical Inc. received breakthrough device designation for its intravascular lithotripsy (IVL) therapy, used for lithotripsy and was long used to eliminate kidney stones.

Thus, these factors are projected to contribute to the Urolithiasis Management Devices market during the forecasted period.

The rising adoption of Urolithiasis Management Devices in the country would result in the rising demand for treatments that make use of Urolithiasis Management Devices, which in turn would provide a conducive growth environment for the United States Urolithiasis Management Devices market as well as the North American region. Therefore, the interplay of various factors such as the presence of a large patient population, encouraging reimbursement policies as well as new product launches in the region is expected to boost the North America Urolithiasis Management Devices market during the forecast period.

Urolithiasis Management Devices Market Key Players:

Some of the key market players operating in the Urolithiasis Management Devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus, General Electric Company (GE Healthcare), ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMINSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

Recent Developmental Activities in the Urolithiasis Management Devices Market:

In March 2022, Boston Scientific acquired Lumenis in a USD 1.07 billion deal. With this acquisition, Boston Scientific has strengthened its product portfolio for Lithotripsy devices. This will further add to the growth of the Global Urolithiasis Management Devices market.

In March 2022, Dornier MedTech GmbH became the world's first integrated urology company to be certified by the European Union's Medical Device Regulation (MDR). Dornier achieved the certification for its Class IIb products: Dornier Delta® III, one of the most powerful lithotripters that utilize Dornier's Extracorporeal Shock Wave Lithotripsy (ESWL) technology; and the Dornier UIMS(TM), a state-of-the-art information management software providing enhanced imaging and efficiency to support clinicians in treating kidney stones.

In August 2020, Olympus Winter & Ibe GmbH received the US FDA approval for OES Elite Ureteroscopes and Accessories under regulatory class II for endoscopic observation and therapy in the ureters, urethra, and urinary bladder.

Key Takeaways from the Urolithiasis Management Devices Market Report Study

  • Market size analysis for current Urolithiasis Management Devices market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Urolithiasis Management Devices market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global Urolithiasis Management Devices market.
  • Various opportunities available for the other competitor in the Urolithiasis Management Devices market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current Urolithiasis Management Devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Urolithiasis Management Devices market growth in the coming future?

Target Audience who can be benefited from this Urolithiasis Management Devices Market Report Study

  • Urolithiasis Management Devices products providers
  • Research organizations and consulting companies
  • Urolithiasis Management Devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Urolithiasis Management Devices
  • Various End-users who want to know more about the Urolithiasis Management Devices market and latest technological developments in the Urolithiasis Management Devices market.

Frequently Asked Questions for the Urolithiasis Management Devices Market:

1. What is Urolithiasis Management Devices?

Urolithiasis Management Devices are devices used to manage Kidney stones (also called renal calculi, nephrolithiasis, or urolithiasis) that form inside kidneys.

2. What is the market for Global Urolithiasis Management Devices?

The global urolithiasis management devices market was valued at USD 1,531.08 million in 2023, growing at a CAGR of 4.27% during the forecast period from 2024 to 2030 to reach USD 1,963.12 million by 2030.

3. What are the drivers for the Global Urolithiasis Management Devices Market?

The Urolithiasis Management Devices market is witnessing a positive market growth owing to the rising prevalence of urolithiasis or nephrolithiasis. In addition, sedentary lifestyle such as obesity which is a risk factor for the development of kidney stones, innovation in product design, increased risk of end-stage renal failure, growing geriatric population, and intensifying awareness for the procedure is thereby contributing to the growth of the Urolithiasis Management Devices market.

4. Who are the key players operating in the Global Urolithiasis Management Devices Market?

Some of the key market players operating in the Urolithiasis Management Devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus, General Electric Company (GE Healthcare), ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMINSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

5. Which region has the highest share in Urolithiasis Management Devices Market?

North America is expected to hold the highest share in the revenue in the Urolithiasis Management Devices market during the forecast period. Factors such as the growing prevalence of stone formations causing urolithiasis and increased risk of end-stage renal disease among the population, rising product approvals, are expected to aid in the growth of the North America Urolithiasis Management Devices Market in this region.

Table of Contents

1.Urolithiasis Management Devices Market Report Introduction

2.Urolithiasis Management Devices Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory and Patent Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Urolithiasis Management Devices Market Key Factors Analysis

  • 4.1. Urolithiasis Management Devices Market Drivers
    • 4.1.1. The Rising Prevalence of Urolithiasis or Nephrolithiasis
    • 4.1.2. Sedentary Lifestyle as a Risk Factor for the Development of Kidney Stones
    • 4.1.3. Innovation in Product Design
    • 4.1.4. Increased Risk of End-Stage Renal Failure
    • 4.1.5. Growing Geriatric Population
  • 4.2. Urolithiasis Management Devices Market Restraints and Challenges
    • 4.2.1. The High Cost of Ureteroscope Devices
    • 4.2.2. The Postoperative Complications
  • 4.3. Urolithiasis Management Devices Market Opportunities
    • 4.3.1. Need For Advanced Devices
    • 4.3.2. Growing Opportunities in Single-Use Ureteroscope

5. Urolithiasis Management Devices Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Urolithiasis Management Devices Market

7. Urolithiasis Management Devices Market Layout

  • 7.1. By Type
    • 7.1.1. Diagnostics
      • 7.1.1.1. X-ray
      • 7.1.1.2. Computed Tomography
      • 7.1.1.3. Ultrasound
      • 7.1.1.4. Others
    • 7.1.2. Treatment
      • 7.1.2.1. Shock Wave Lithotripters
      • 7.1.2.1.1. Intracorporeal
      • 7.1.2.1.2. Extracorporeal
      • 7.1.2.2. Ureteroscopes
      • 7.1.2.2.1. Semi-Rigid
      • 7.1.2.2.2. Flexible
      • 7.1.2.3. Stone Retrieval Devices
      • 7.1.2.4. Others
  • 7.2. By End-User
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States
      • 7.3.1.2. Canada
      • 7.3.1.3. Mexico
    • 7.3.2. Europe
      • 7.3.2.1. France
      • 7.3.2.2. Germany
      • 7.3.2.3. United Kingdom
      • 7.3.2.4. Italy
      • 7.3.2.5. Spain
      • 7.3.2.6. Russia
      • 7.3.2.7. Rest of Europe
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China
      • 7.3.3.2. Japan
      • 7.3.3.3. India
      • 7.3.3.4. Australia
      • 7.3.3.5. South Korea
      • 7.3.3.6. Rest of Asia Pacific
    • 7.3.4. Rest of the World (RoW)

8. Urolithiasis Management Devices Market Global Company Share Analysis - Key 3-5 Companies

9. Urolithiasis Management Devices Market Company and Product Profiles

  • 9.1. Boston Scientific Corporation
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. EMS Urology
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Advin Health Care
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Inceler Medikal Co. Ltd.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Walz Elektronik GmbH
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. DirexGroup
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Medispec Ltd.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Richard Wolf GmbH
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. STORZ MEDICAL AG
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Olympus
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. General Electric Company (GE Healthcare)
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. ESAOTE SPA
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. BK Medical Holding Company, Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Hitachi Medical Systems
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Laborie
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. DRAMINSKI S. A.
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. ACE Medical Devices Pvt. Ltd.
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Siemens Healthcare Private Limited
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. Vimex Sp. z o.o.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Urolithiasis Management Devices Market in Global (2021-2030)
  • Table 4: Urolithiasis Management Devices Market in Global by Diagnostics (2021-2030)
  • Table 5: Urolithiasis Management Devices Market in Global by Treatment (2021-2030)
  • Table 6: Urolithiasis Management Devices Market in Global by End User (2021-2030)
  • Table 7: Urolithiasis Management Devices Market in Global by Geography (2021-2030)
  • Table 8: Urolithiasis Management Devices Market in North America (2021-2030)
  • Table 9: Urolithiasis Management Devices Market in North America by Country (2021-2030)
  • Table 10: Urolithiasis Management Devices Market in the US (2021-2030)
  • Table 11: Urolithiasis Management Devices Market in Canada (2021-2030)
  • Table 12: Urolithiasis Management Devices Market in Mexico (2021-2030)
  • Table 13: Urolithiasis Management Devices Market in Europe (2021-2030)
  • Table 14: Urolithiasis Management Devices Market in Europe by Country (2021-2030)
  • Table 15: Urolithiasis Management Devices Market in France (2021-2030)
  • Table 16: Urolithiasis Management Devices Market in Germany (2021-2030)
  • Table 17: Urolithiasis Management Devices Market in the United Kingdom (2021-2030)
  • Table 18: Urolithiasis Management Devices Market in Italy (2021-2030)
  • Table 19: Urolithiasis Management Devices Market in Spain (2021-2030)
  • Table 20: Urolithiasis Management Devices Market in Russia (2021-2030)
  • Table 21: Urolithiasis Management Devices Market in Rest of Europe (2021-2030)
  • Table 22: Urolithiasis Management Devices Market in APAC (2021-2030)
  • Table 23: Urolithiasis Management Devices Market in APAC by Country (2021-2030)
  • Table 24: Urolithiasis Management Devices Market in China (2021-2030)
  • Table 25: Urolithiasis Management Devices Market in Japan (2021-2030)
  • Table 26: Urolithiasis Management Devices Market in India (2021-2030)
  • Table 27: Urolithiasis Management Devices Market in Australia (2021-2030)
  • Table 28: Urolithiasis Management Devices Market in South Korea (2021-2030)
  • Table 29: Urolithiasis Management Devices Market in Rest of APAC (2021-2030)
  • Table 30: Urolithiasis Management Devices Market in Rest of World (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Urolithiasis Management Devices Market in Global (2021-2030)
  • Figure 4: Urolithiasis Management Devices Market in Global by Diagnostics (2021-2030)
  • Figure 5: Urolithiasis Management Devices Market in Global by Treatment (2021-2030)
  • Figure 6: Urolithiasis Management Devices Market in Global by End User (2021-2030)
  • Figure 7: Urolithiasis Management Devices Market in Global by Geography (2021-2030)
  • Figure 8: Urolithiasis Management Devices Market in North America (2021-2030)
  • Figure 9: Urolithiasis Management Devices Market in North America by Country (2021-2030)
  • Figure 10: Urolithiasis Management Devices Market in the US (2021-2030)
  • Figure 11: Urolithiasis Management Devices Market in Canada (2021-2030)
  • Figure 12: Urolithiasis Management Devices Market in Mexico (2021-2030)
  • Figure 13: Urolithiasis Management Devices Market in Europe (2021-2030)
  • Figure 14: Urolithiasis Management Devices Market in Europe by Country (2021-2030)
  • Figure 15: Urolithiasis Management Devices Market in France (2021-2030)
  • Figure 16: Urolithiasis Management Devices Market in Germany (2021-2030)
  • Figure 17: Urolithiasis Management Devices Market in the United Kingdom (2021-2030)
  • Figure 18: Urolithiasis Management Devices Market in Italy (2021-2030)
  • Figure 19: Urolithiasis Management Devices Market in Spain (2021-2030)
  • Figure 20: Urolithiasis Management Devices Market in Russia (2021-2030)
  • Figure 21: Urolithiasis Management Devices Market in Rest of Europe (2021-2030)
  • Figure 22: Urolithiasis Management Devices Market in APAC (2021-2030)
  • Figure 23: Urolithiasis Management Devices Market in APAC by Country (2021-2030)
  • Figure 24: Urolithiasis Management Devices Market in China (2021-2030)
  • Figure 25: Urolithiasis Management Devices Market in Japan (2021-2030)
  • Figure 26: Urolithiasis Management Devices Market in India (2021-2030)
  • Figure 27: Urolithiasis Management Devices Market in Australia (2021-2030)
  • Figure 28: Urolithiasis Management Devices Market in South Korea (2021-2030)
  • Figure 29: Urolithiasis Management Devices Market in Rest of APAC (2021-2030)
  • Figure 30: Urolithiasis Management Devices Market in Rest of World (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis